SCHEMBL3161925

SCHEMBL3161925

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(CNC)cc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
NAMPT P43490 3/20 0.48
RXFP1 Q9HBX9 1/20 0.47
SMN1; SMN2 Q16637 5/20 0.45
GAA P10253 3/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 7/20 0.45
MEN1 O00255 6/20 0.45
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SENP1 Q9P0U3 1/20 0.41
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3161917 1.00 MAPT (0.48) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL480619 0.93 SMN1; SMN2 (0.54) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL480620 0.93 SMN1; SMN2 (0.54) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL2122209 0.93 RXFP1 (0.49) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL2122210 0.93 RXFP1 (0.49) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL7489623 0.92 SENP1 (0.50) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL3157262 0.92 MAPT (0.48) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL3157274 0.92 MAPT (0.48) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL480468 0.92 SENP1 (0.50) MAPTNAMPTRXFP1SMN1; SMN2GAA
SCHEMBL480469 0.92 SENP1 (0.50) MAPTNAMPTRXFP1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224170-B9 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 2017-11-22 EP disclosed
EP-2157081-A1 Indolinones substituted in six locations, their manufacture and their application as medicine Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2010-02-24 EP disclosed
EP-1224170-B1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 2009-08-12 EP disclosed
US-6762180-B1 Substituted indolines which inhibit receptor tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-07-13 US disclosed